RNA Biomarkers in Tissue Samples From Infants With Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01229124|
Recruitment Status : Completed
First Posted : October 27, 2010
Last Update Posted : May 17, 2016
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in RNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying RNA biomarkers in tissue samples from infants with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: RNA analysis Genetic: nucleic acid sequencing Genetic: reverse transcriptase-polymerase chain reaction Other: laboratory biomarker analysis|
- Sequence the microRNAs present in 20 infant AML samples as a pilot study.
- Compare microRNAs present in infant AML samples to infant ALL samples that are being concurrently sequenced in a separate study to identify lineage- and translocation-specific microRNAs.
OUTLINE: This is a multicenter study.
Previously collected cryopreserved cells from diagnosis are sequenced using reverse transcriptase-PCR.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||SCOR in Targeted Therapies for Infant Leukemias Project 4: MicroRNA Sequencing of Infant AML|
|Study Start Date :||October 2010|
|Primary Completion Date :||May 2016|
|Study Completion Date :||May 2016|
- Sequence of the microRNAs present in 20 infant acute myeloid leukemia (AML) samples
- Comparison of microRNAs present in infant AML samples to infant acute lymphoblastic leukemia samples to identify lineage- and translocation-specific microRNAs
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01229124
|Principal Investigator:||Michael Cleary, MD||Stanford University|